Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA)

Bone Marrow Transplantation volume 36, pages 873–877 (2005)Cite this article

Summary:

A total of 85 allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis treated with amphotericin B lipid complex (ABLC) were identified from the Collaborative Exchange of Antifungal Research (CLEAR) database. Of these patients, 78% (66/85) presented with pulmonary aspergillosis. Graft-versus-host disease (GVHD) was present in 24 of 85 patients. The response rate to ABLC was 31% (26/85) overall and 21% (5/24) in patients with GVHD. The overall response rate to first-line ABLC treatment was 41% (11/27). Four of nine (44%) patients with GVHD responded to first-line treatment with ABLC, while only one of 13 (8%) responded to ABLC as second-line therapy. Five of 18 (28%) and four of 14 (29%) patients, respectively, responded to sequential or concurrent treatment with ABLC and itraconazole. None of seven patients responded who continued receiving itraconazole after the start of ABLC therapy. At the end of ABLC therapy, serum creatinine had doubled in 12% of patients (10/85), and 2% (2/85) had developed a requirement for dialysis. These data suggest that ABLC, especially when administered as first-line therapy, can result in clinical response even in the most immunocompromised patients, that is, HCT recipients with GVHD, with minimal effects on renal function.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Baddley JW, Stroud TP, Salzman D, Pappas PG . Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319–1324.

    Article  CAS  Google Scholar 

  2. Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909–917.

    Article  Google Scholar 

  3. Lin SJ, Schranz J, Teutsch SM . Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358–366.

    Article  CAS  Google Scholar 

  4. Wald A, Leisenring W, van Burik JA, Bowden RA . Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459–1466.

    Article  CAS  Google Scholar 

  5. Gallis HA, Drew RH, Pickard WW . Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308–329.

    Article  CAS  Google Scholar 

  6. Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29: 1402–1407.

    Article  CAS  Google Scholar 

  7. Harbarth S, Pestotnik SL, Lloyd JF et al. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001; 111: 528–534.

    Article  CAS  Google Scholar 

  8. Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686–693.

    Article  CAS  Google Scholar 

  9. Gubbins PO, Penzak SR, Polston S et al. Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients. Pharmacotherapy 2002; 22: 961–971.

    Article  CAS  Google Scholar 

  10. Zager RA, O'Quigley J, Zager BK et al. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis 1989; 13: 210–216.

    Article  CAS  Google Scholar 

  11. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415.

    Article  CAS  Google Scholar 

  12. Pappas PG . Amphotericin B lipid complex in the treatment of invasive fungal infections: results of the Collaborative Exchange of Antifungal Research (CLEAR), an industry-supported patient registry. Clin Infect Dis 2005; 40 (Suppl. 6): S379–S383.

    Article  Google Scholar 

  13. Alexander BD, Wingard JR . Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 2005; 40 (Suppl 6): S414–S421.

    Article  CAS  Google Scholar 

  14. Hooshmand-Rad R, Reed MD, Chu A et al. Retrospective study of the renal effects of Amphotericin B Lipid Complex when used at higher than recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections. Clin Ther 2004; 26: 1652–1662.

    Article  CAS  Google Scholar 

  15. Cockcroft DW, Gault MH . Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41.

    Article  CAS  Google Scholar 

  16. Bowden R, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359–366.

    Article  CAS  Google Scholar 

  17. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563–1571.

    Article  CAS  Google Scholar 

  18. Wingard JR . Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 1997; 19: 343–347.

    Article  CAS  Google Scholar 

  19. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14.

    Article  CAS  Google Scholar 

  20. Wong-Beringer A, Jacobs RA, Guglielmo BJ . Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27: 603–618.

    Article  CAS  Google Scholar 

  21. Luke RG, Boyle JA . Renal effects of amphotericin B lipid complex. Am J Kidney Dis 1998; 31: 780–785.

    Article  CAS  Google Scholar 

  22. Kontoyiannis DP, Lewis RE . Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol 2004; 126: 165–175.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Gigi Xiang and Sherry Yu for expert statistical analysis support.

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, City of Hope National Medical Center, Duarte, CA, USA

    J I Ito

  2. Division of Infectious Diseases, Wayne State University/Detroit Medical Center Program, Detroit, MI, USA

    P H Chandrasekar

  3. ProSanos Corporation, La Jolla, CA, USA

    R Hooshmand-Rad

Authors
  1. J I Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P H Chandrasekar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Hooshmand-Rad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J I Ito.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ito, J., Chandrasekar, P. & Hooshmand-Rad, R. Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA). Bone Marrow Transplant 36, 873–877 (2005). https://doi.org/10.1038/sj.bmt.1705143

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705143

Keywords

This article is cited by

Search

Advanced search

Quick links